| REVIEW ARTICLE |
|
| Year : 2012 | Volume
: 1
| Issue : 2 | Page : 53-60 |
|
|
Various treatment options for benign prostatic hyperplasia: A current update
Alankar Shrivastava, Vipin Bihari Gupta
Department of Pharmaceutical Analysis, B. R. Nahata College of Pharmacy, Mandsaur, India
Correspondence Address:
Alankar Shrivastava
Department of Pharmaceutical Analysis, B. R. Nahata College of Pharmacy, Mhow-Neemuch Road, Mandsaur - 458 001
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/2278-0521.100940
|
|
|
In benign prostatic hyperplasia (BPH), there will be a sudden impact on overall quality of life of the patient. This disease occurs normally at the age of 40 and above and is also associated with sexual dysfunction. Thus, there is a need to update our knowledge on the current medications for this disease. The presented review provides information on medications available for BPH. Phytotherapies with some improvements in BPH are also included. Relevant articles were identified through a search of the English language literature indexed on MEDLINE, PUBMED, ScienceDirect, and the proceedings of scientific meetings. The search terms were benign prostatic hyperplasia, BPH, medications for BPH, drugs for BPH, combination therapies for BPH, and phytotherapies for BPH. Medications including watchful waitings, β1 -adrenoreceptor blockers, 5β-reductase inhibitors, and combination therapies including tamsulosin-dutasteride, doxazosin-finasteride, terazosin-finasteride, tolterodine-tamsulosin, and rofecoxib-finasteride were found. Herbal remedies such as Cernilton, Saxifraga stolonifera, Zi-Shen Pill (ZSPE), Orbignya speciosa, Phellodendron amurense, Ganoderma lucidum, Serenoa repens, pumpkin extract, and Lepidium meyenii (Red Maca) showing some improvement on BPH are included. Other than these, discussions on transurethral resection of prostate (TURP) and minimally invasive therapies (MITs) are also included. Recent advancements in terms of newly synthesized molecules are also discussed. Specific β1 -adrenoreceptor blockers such as tamsulosin and alfuzosin will remain the preferred choice of urologists for symptom relief. Medications with combination therapies still need more investigation to establish their preference in the initial stage for fast symptom relief, reduced prostate growth, and obviously for reducing the need for BPH-related surgery. Due to lack of proper evidence, phytotherapies are not gaining much advantage. MITs and TURP are expensive and are rarely supported by healthcare systems. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
